5HJ Stock Overview
A clinical-stage medical device company, focuses on the development of various bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
enVVeno Medical Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.08 |
| 52 Week High | US$6.05 |
| 52 Week Low | US$2.70 |
| Beta | 1.22 |
| 11 Month Change | -1.28% |
| 3 Month Change | -34.75% |
| 1 Year Change | -12.99% |
| 33 Year Change | -51.11% |
| 5 Year Change | n/a |
| Change since IPO | -61.50% |
Recent News & Updates
Recent updates
Shareholder Returns
| 5HJ | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -1.9% | -1.0% | -0.02% |
| 1Y | -13.0% | -7.3% | 8.2% |
Return vs Industry: 5HJ underperformed the German Medical Equipment industry which returned -8.4% over the past year.
Return vs Market: 5HJ underperformed the German Market which returned 7.4% over the past year.
Price Volatility
| 5HJ volatility | |
|---|---|
| 5HJ Average Weekly Movement | 9.2% |
| Medical Equipment Industry Average Movement | 5.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 5HJ's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 5HJ's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 31 | Robert Berman | www.envveno.com |
enVVeno Medical Corporation, a clinical-stage medical device company, focuses on the development of various bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous diseases. The company’s lead product is the VenoValve, a surgical implant being developed for the treatment of venous Chronic Venous Insufficiency. Its VenoValve is implanted in the femoral vein and acts as a one-way valve to help restore proper blood flow in the leg; and enVVe, a non-surgical, transcatheter based replacement venous valve for the treatment of CVI.
enVVeno Medical Corporation Fundamentals Summary
| 5HJ fundamental statistics | |
|---|---|
| Market cap | €55.57m |
| Earnings (TTM) | -€20.40m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.8x
P/E RatioIs 5HJ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 5HJ income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$21.24m |
| Earnings | -US$21.24m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.21 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 5HJ perform over the long term?
See historical performance and comparison